- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01254279
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients.
Please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Box Hill, Australien, 3128
- Investigational Site Number 036004
-
Campbelltown, Australien, 2560
- Investigational Site Number 036020
-
Camperdown, Australien, 2050
- Investigational Site Number 036001
-
Camperdown, Australien, 2050
- Investigational Site Number 036002
-
Douglas, Australien, 4814
- Investigational Site Number 036011
-
Nambour, Australien, 4560
- Investigational Site Number 036019
-
North Adelaide, Australien, 5006
- Investigational Site Number 036023
-
Parkville, Australien, 3050
- Investigational Site Number 036008
-
Perth, Australien
- Investigational Site Number 036005
-
Port Macquarie, Australien
- Investigational Site Number 036003
-
Randwick, Australien, 2031
- Investigational Site Number 036025
-
South Brisbane, Australien, 4101
- Investigational Site Number 036009
-
South Brisbane, Australien, 4101
- Investigational Site Number 036022
-
Southport, Australien, 4215
- Investigational Site Number 036017
-
St Leonards, Australien, 2065
- Investigational Site Number 036012
-
Sydney, Australien, 2076
- Investigational Site Number 036010
-
Sydney, Australien
- Investigational Site Number 036013
-
Sydney, Australien
- Investigational Site Number 036014
-
Tweed Heads, Australien
- Investigational Site Number 036016
-
Wendouree, Australien, 3355
- Investigational Site Number 036024
-
Westmead, Australien, 2145
- Investigational Site Number 036007
-
Wodonga, Australien
- Investigational Site Number 036015
-
-
-
-
-
Brugge, Belgien, 8000
- Investigational Site Number 056002
-
Bruxelles, Belgien, 1020
- Investigational Site Number 056007
-
Haine St Paul, Belgien, 7100
- Investigational Site Number 056003
-
Liège, Belgien, 4000
- Investigational Site Number 056005
-
Ottignies, Belgien, 1340
- Investigational Site Number 056004
-
Roeselare, Belgien, 8800
- Investigational Site Number 056001
-
Tournai, Belgien, 7500
- Investigational Site Number 056006
-
-
-
-
-
Banja Luka, Bosnien och Hercegovina
- Investigational Site Number 070003
-
Sarajevo, Bosnien och Hercegovina
- Investigational Site Number 070001
-
Zenica, Bosnien och Hercegovina
- Investigational Site Number 070002
-
-
-
-
-
Plovdiv, Bulgarien, 4000
- Investigational Site Number 100004
-
Sofia, Bulgarien, 1527
- Investigational Site Number 100001
-
Sofia, Bulgarien, 1756
- Investigational Site Number 100003
-
Sofia, Bulgarien
- Investigational Site Number 100002
-
-
-
-
-
Cph Ø, Danmark, 2100
- Investigational Site Number 208-001
-
Herlev, Danmark, 2730
- Investigational Site Number 208-002
-
Odense, Danmark, 5000
- Investigational Site Number 208-003
-
-
-
-
-
Manila, Filippinerna, 1000
- Investigational Site Number 608001
-
-
-
-
-
Helsinki, Finland, 00180
- Investigational Site Number 246002
-
Seinäjoki, Finland, 60220
- Investigational Site Number 246001
-
-
-
-
-
Chennai, Indien, 600035
- Investigational Site Number 356004
-
Gurgaon, Indien, 12201
- Investigational Site Number 356006
-
New Delhi, Indien, 110029
- Investigational Site Number 356001
-
New Delhi, Indien, 110085
- Investigational Site Number 356002
-
Trivandrum, Indien, 695011
- Investigational Site Number 356005
-
-
-
-
-
Cork, Irland
- Investigational Site Number 372004
-
Dublin 24, Irland
- Investigational Site Number 372003
-
Dublin 7, Irland
- Investigational Site Number 372001
-
Dublin 7, Irland
- Investigational Site Number 372002
-
-
-
-
-
Arezzo, Italien, 06156
- Investigational Site Number 380-001
-
Aviano, Italien
- Investigational Site Number 380-011
-
Bari, Italien
- Investigational Site Number 380-025
-
Bergamo, Italien, 24128
- Investigational Site Number 380-007
-
Bologna, Italien
- Investigational Site Number 380-015
-
Fano, Italien
- Investigational Site Number 380-021
-
Firenze, Italien
- Investigational Site Number 380-012
-
Genova, Italien, 16132
- Investigational Site Number 380-003
-
Genova, Italien, 16132
- Investigational Site Number 380-005
-
Lecce, Italien
- Investigational Site Number 380-014
-
Messina, Italien
- Investigational Site Number 380-023
-
Milano, Italien
- Investigational Site Number 380-018
-
Milano, Italien
- Investigational Site Number 380-022
-
Napoli, Italien, 80131
- Investigational Site Number 380-006
-
Napoli, Italien, 80131
- Investigational Site Number 380-010
-
Napoli, Italien
- Investigational Site Number 380-027
-
Orbassano, Italien, 10043
- Investigational Site Number 380-004
-
Padova, Italien
- Investigational Site Number 380-017
-
Parma, Italien, 43100
- Investigational Site Number 380-002
-
Roma, Italien, 00152
- Investigational Site Number 380-009
-
Roma, Italien, 00189
- Investigational Site Number 380-008
-
Rozzano, Italien, 20089
- Investigational Site Number 380-024
-
San Giovanni Rotondo, Italien
- Investigational Site Number 380-020
-
Sassari, Italien
- Investigational Site Number 380-013
-
Taormina, Italien
- Investigational Site Number 380-016
-
-
-
-
-
Kitchener, Kanada, N2G1G3
- Investigational Site Number 124012
-
Laval, Kanada, H7M3L9
- Investigational Site Number 124009
-
London, Kanada, N6A 4L6
- Investigational Site Number 124004
-
Moncton, Kanada, E1C6Z8
- Investigational Site Number 124007
-
Montreal, Kanada, H2L 4M1
- Investigational Site Number 124001
-
Montreal, Kanada, H3G1A4
- Investigational Site Number 124011
-
Quebec, Kanada, G1R 2J6
- Investigational Site Number 124010
-
Toronto, Kanada, M4N3M5
- Investigational Site Number 124003
-
Toronto, Kanada, M5G2M9
- Investigational Site Number 124002
-
Winnipeg, Kanada, R3E0V9
- Investigational Site Number 124006
-
-
-
-
-
Almaty, Kazakstan
- Investigational Site Number 398001
-
Shymkent, Kazakstan
- Investigational Site Number 398003
-
-
-
-
-
Zagreb, Kroatien, 10000
- Investigational Site Number 191-001
-
-
-
-
-
Niederkorn, Luxemburg, 4602
- Investigational Site Number 442001
-
-
-
-
-
Georgetown, Malaysia, 10050
- Investigational Site Number 458002
-
Kuala Lumpur, Malaysia, 59100
- Investigational Site Number 458001
-
Kuching, Malaysia, 93586
- Investigational Site Number 458003
-
-
-
-
-
Durango, Mexiko, 34000
- Investigational Site Number 484002
-
Irapuato, Mexiko, 36500
- Investigational Site Number 484006
-
Toluca, Mexiko, 50180
- Investigational Site Number 484005
-
Zapopan, Mexiko, 45200
- Investigational Site Number 484001
-
-
-
-
-
Gdansk, Polen, 80-952
- Investigational Site Number 616-001
-
-
-
-
-
Coimbra, Portugal, 3000-75
- Investigational Site Number 620002
-
Lisboa, Portugal, 1099-023
- Investigational Site Number 620003
-
Lisboa, Portugal, 1649-035
- Investigational Site Number 620004
-
Porto, Portugal, 4200-072
- Investigational Site Number 620001
-
Setúbal, Portugal, 2910-446
- Investigational Site Number 620005
-
-
-
-
-
Bucharest, Rumänien, 030171
- Investigational Site Number 642001
-
Cluj-Napoca, Rumänien, 400015
- Investigational Site Number 642002
-
Timisoara, Rumänien, 300239
- Investigational Site Number 642003
-
-
-
-
-
Belgrade, Serbien
- Investigational Site Number 688001
-
Belgrade, Serbien
- Investigational Site Number 688002
-
-
-
-
-
Singapore, Singapore, 169610
- Investigational Site Number 702002
-
Singapore, Singapore, 258499
- Investigational Site Number 702001
-
-
-
-
-
Bratislava, Slovakien, 83310
- Investigational Site Number 703001
-
Kosice, Slovakien, 04190
- Investigational Site Number 703002
-
-
-
-
-
Barcelona, Spanien, 08025
- Investigational Site Number 724018
-
Barcelona, Spanien, 08036
- Investigational Site Number 724019
-
Castellón de la Plana, Spanien, 12002
- Investigational Site Number 724023
-
Córdoba, Spanien, 14004
- Investigational Site Number 724020
-
Elche, Spanien, 03203
- Investigational Site Number 724025
-
Granada, Spanien, 18014
- Investigational Site Number 724017
-
Guadalajara, Spanien, 19002
- Investigational Site Number 724006
-
L'Hospitalet de Llobregat, Spanien, 08907
- Investigational Site Number 724011
-
La Coruña, Spanien, 15006
- Investigational Site Number 724002
-
León, Spanien, 24071
- Investigational Site Number 724010
-
Madrid, Spanien, 28007
- Investigational Site Number 724003
-
Madrid, Spanien, 28040
- Investigational Site Number 724012
-
Madrid, Spanien, 28041
- Investigational Site Number 724007
-
Manresa, Spanien, 08243
- Investigational Site Number 724008
-
Málaga, Spanien, 29010
- Investigational Site Number 724021
-
Oviedo, Spanien, 33006
- Investigational Site Number 724009
-
Pamplona, Spanien, 31008
- Investigational Site Number 724022
-
San Cristóbal de La Laguna - Sta. Cruz de Tenerife, Spanien, 38320
- Investigational Site Number 724005
-
Santander, Spanien, 39008
- Investigational Site Number 724016
-
Santiago de Compostela, Spanien, 15706
- Investigational Site Number 724015
-
Sevilla, Spanien, 41013
- Investigational Site Number 724024
-
Terrassa, Spanien, 08221
- Investigational Site Number 724004
-
Valencia, Spanien, 46009
- Investigational Site Number 724013
-
Valencia, Spanien, 46015
- Investigational Site Number 724014
-
Zaragoza, Spanien, 50009
- Investigational Site Number 724001
-
-
-
-
-
Birmingham, Storbritannien, B152TH
- Investigational Site Number 826011
-
Bristol, Storbritannien, BS28ED
- Investigational Site Number 826002
-
Glasgow, Storbritannien, G116NT
- Investigational Site Number 826003
-
Leeds, Storbritannien, LS97TF
- Investigational Site Number 826013
-
London, Storbritannien, SE19RT
- Investigational Site Number 826009
-
Manchester, Storbritannien, M204BX
- Investigational Site Number 826012
-
Nottingham, Storbritannien, NG51PB
- Investigational Site Number 826005
-
Preston, Storbritannien, PR24QF
- Investigational Site Number 826008
-
Sutton, Storbritannien, SM25PT
- Investigational Site Number 826001
-
Torquay, Storbritannien, TQ27AA
- Investigational Site Number 826007
-
Whitechurch, Storbritannien, CF142TL
- Investigational Site Number 826006
-
Wirral, Storbritannien, CH634JY
- Investigational Site Number 826004
-
-
-
-
-
Umeå, Sverige, 90185
- Investigational Site Number 752-002
-
Uppsala, Sverige, 75185
- Investigational Site Number 752-001
-
-
-
-
-
Kaohsiung Hsien,, Taiwan
- Investigational Site Number 005
-
Taichung, Taiwan, 407
- Investigational Site Number 004
-
Taipei, Taiwan, 100
- Investigational Site Number 002
-
Taipei, Taiwan
- Investigational Site Number 003
-
Tao Yuan Hsien, Taiwan
- Investigational Site Number 001
-
-
-
-
-
Brno, Tjeckien, 65653
- Investigational Site Number 203001
-
-
-
-
-
Budapest, Ungern, 1032
- Investigational Site Number 348001
-
Szolnok, Ungern, 5000
- Investigational Site Number 348002
-
Szombathely, Ungern, 9700
- Investigational Site Number 348003
-
Veszprém, Ungern, 8200
- Investigational Site Number 348004
-
-
-
-
-
Linz, Österrike, 4010
- Investigational Site Number 040-004
-
Salzburg, Österrike
- Investigational Site Number 040-005
-
Vienna, Österrike
- Investigational Site Number 040-003
-
Wien, Österrike, 1090
- Investigational Site Number 040-002
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Metastatic Hormone Refractory Prostate Cancer (mHRPC) previously treated with a docetaxel-containing regimen
- Disease Progression during or after docetaxel-containing regimen for mHRPC
- Surgical or medical castration
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2
- Life-expectancy ≥3 months
- Adequate bone marrow, liver, and renal function: Neutrophils> 1500 /mm3; Hemoglobin > 10 g/dL; Platelets > 100 x109/L; Bilirubin < ULN; SGOT (AST) < 1.5xULN; SGPT (ALT) < 1.5xULN; Creatinine < 1.5xULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance < 60 mL/min should be excluded.
Exclusion criteria:
- Prior radiotherapy to ≥ 40% of bone marrow
- Prior radionuclide therapy (samarium-153, strontium-89, P-32…)
- Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment
- Active grade ≥2 peripheral neuropathy
- Active grade ≥2 stomatitis
- Active infection requiring systemic antibiotic or anti-fungal medication
- Active cancer (other than mHRPC) including prior malignancy from which the patient has been disease-free for ≤5 years (except superficial basal cell skin cancer)
- Known brain or leptomeningeal involvement
- History of severe hypersensitivity reaction (≥grade 3) to docetaxel
- History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
- History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone
- Uncontrolled severe illness or medical condition (including uncontrolled cardiac arrhythmias, angina pectoris, hypertension or diabetes mellitus). History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed.
- Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5
- Participation in a clinical trial with any investigational drug
- Patient with reproductive potential not implementing accepted and effective method of contraception
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Cabazitaxel
Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
|
Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen
Tidsram: Up to 30 weeks
|
Up to 30 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
To document safety of cabazitaxel in these patients
Tidsram: Up to 35 weeks
|
Up to 35 weeks
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, James ND, Mason MD, Kumar S, Bottomley D, Lydon A, Chowdhury S, Wylie J, de Bono JS. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015 Dec;116(6):880-7. doi: 10.1111/bju.13069. Epub 2015 Jun 16.
- Castellano D, Anton Aparicio LM, Esteban E, Sanchez-Hernandez A, Germa JR, Batista N, Maroto P, Perez-Valderrama B, Luque R, Mendez-Vidal MJ; cabazitaxel EAP study. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CABAZ_C_05331
- 2010-021128-92 (EudraCT-nummer)
- U1111-1115-2476 (Annan identifierare: UTN)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Prostatacancer Metastaserande
-
I-Mab Biopharma Co. Ltd.Inte längre tillgängligSolid Tumor Metastatic Cancer Advanced Cancer
-
PfizerAvslutadBRAF eller NRAS Mutant Metastatic MelanomFörenta staterna, Nederländerna, Italien, Tyskland, Schweiz
-
Sunnybrook Health Sciences CentrePfizerAvslutadClear Cell Metastatic Renal Cell CarcinomKanada
-
Association Pour La Recherche des Thérapeutiques...AvslutadClear Cell Metastatic Renal Cell CarcinomFrankrike
Kliniska prövningar på CABAZITAXEL
-
Jeffrey Yachnin M.D., PhD.SanofiAvslutadMetastaserande kastrationsresistent prostatacancerSverige
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiAvslutad
-
Institut für Klinische Krebsforschung IKF GmbH...Avslutad
-
Gustave Roussy, Cancer Campus, Grand ParisSanofiOkändIcke-seminomatösa könscellstumörerFrankrike
-
Rambam Health Care CampusAvslutad
-
Vejle HospitalSanofiAvslutad
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalOkänd
-
University Hospitals Bristol and Weston NHS Foundation...SanofiAvslutad
-
Brown UniversityAvslutad
-
European Organisation for Research and Treatment...SanofiAvslutadDedifferentierat liposarkomStorbritannien, Belgien, Frankrike, Italien